Ulysses V. A. Silva
Universidade Federal do Rio Grande do Sul
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ulysses V. A. Silva.
Chest | 2014
Luciano C. P. Azevedo; Pedro Caruso; Ulysses V. A. Silva; André P. Torelly; Eliezer Silva; Ederlon Rezende; José J. Netto; Claudio Piras; Suzana M. Lobo; Marcos Freitas Knibel; José Mario Meira Teles; Ricardo. A. Lima; Bruno S. Ferreira; Gilberto Friedman; Álvaro Réa-Neto; Felipe Dal-Pizzol; Fernando A. Bozza; Jorge I. F. Salluh; Márcio Soares
BACKGROUND This study was undertaken to evaluate the clinical characteristics and outcomes of patients with cancer requiring nonpalliative ventilatory support. METHODS This was a secondary analysis of a prospective cohort study conducted in 28 Brazilian ICUs evaluating adult patients with cancer requiring invasive mechanical ventilation (MV) or noninvasive ventilation (NIV) during the first 48 h of their ICU stay. We used logistic regression to identify the variables associated with hospital mortality. RESULTS Of 717 patients, 263 (37%) (solid tumors = 227; hematologic malignancies = 36) received ventilatory support. NIV was initially used in 85 patients (32%), and 178 (68%) received MV. Additionally, NIV followed by MV occurred in 45 patients (53%). Hospital mortality rates were 67% in all patients, 40% in patients receiving NIV only, 69% when NIV was followed by MV, and 73% in patients receiving MV only (P < .001). Adjusting for the type of admission, newly diagnosed malignancy (OR, 3.59; 95% CI, 1.28-10.10), recurrent or progressive malignancy (OR, 3.67; 95% CI, 1.25-10.81), tumoral airway involvement (OR, 4.04; 95% CI, 1.30-12.56), performance status (PS) 2 to 4 (OR, 2.39; 95% CI, 1.24-4.59), NIV followed by MV (OR, 3.00; 95% CI, 1.09-8.18), MV as initial ventilatory strategy (OR, 3.53; 95% CI, 1.45-8.60), and Sequential Organ Failure Assessment score (each point except the respiratory domain) (OR, 1.15; 95% CI, 1.03-1.29) were associated with hospital mortality. Hospital survival in patients with good PS and nonprogressive malignancy and without tumoral airway involvement was 53%. Conversely, patients with poor functional capacity and cancer progression had unfavorable outcomes. CONCLUSIONS Patients with cancer with good PS and nonprogressive disease requiring ventilatory support should receive full intensive care, because one-half of these patients survive. On the other hand, provision of palliative care should be considered the main goal for patients with poor PS and progressive underlying malignancy.
Chest | 2014
Luciano C. P. Azevedo; Pedro Caruso; Ulysses V. A. Silva; André P. Torelly; Eliezer Silva; Ederlon Rezende; José J. Netto; Claudio Piras; Suzana M. Lobo; Marcos Freitas Knibel; José Mario Meira Teles; Ricardo. A. Lima; Bruno S. Ferreira; Gilberto Friedman; Álvaro Réa-Neto; Felipe Dal-Pizzol; Fernando A. Bozza; Jorge I. F. Salluh; Márcio Soares
BACKGROUND This study was undertaken to evaluate the clinical characteristics and outcomes of patients with cancer requiring nonpalliative ventilatory support. METHODS This was a secondary analysis of a prospective cohort study conducted in 28 Brazilian ICUs evaluating adult patients with cancer requiring invasive mechanical ventilation (MV) or noninvasive ventilation (NIV) during the first 48 h of their ICU stay. We used logistic regression to identify the variables associated with hospital mortality. RESULTS Of 717 patients, 263 (37%) (solid tumors = 227; hematologic malignancies = 36) received ventilatory support. NIV was initially used in 85 patients (32%), and 178 (68%) received MV. Additionally, NIV followed by MV occurred in 45 patients (53%). Hospital mortality rates were 67% in all patients, 40% in patients receiving NIV only, 69% when NIV was followed by MV, and 73% in patients receiving MV only (P < .001). Adjusting for the type of admission, newly diagnosed malignancy (OR, 3.59; 95% CI, 1.28-10.10), recurrent or progressive malignancy (OR, 3.67; 95% CI, 1.25-10.81), tumoral airway involvement (OR, 4.04; 95% CI, 1.30-12.56), performance status (PS) 2 to 4 (OR, 2.39; 95% CI, 1.24-4.59), NIV followed by MV (OR, 3.00; 95% CI, 1.09-8.18), MV as initial ventilatory strategy (OR, 3.53; 95% CI, 1.45-8.60), and Sequential Organ Failure Assessment score (each point except the respiratory domain) (OR, 1.15; 95% CI, 1.03-1.29) were associated with hospital mortality. Hospital survival in patients with good PS and nonprogressive malignancy and without tumoral airway involvement was 53%. Conversely, patients with poor functional capacity and cancer progression had unfavorable outcomes. CONCLUSIONS Patients with cancer with good PS and nonprogressive disease requiring ventilatory support should receive full intensive care, because one-half of these patients survive. On the other hand, provision of palliative care should be considered the main goal for patients with poor PS and progressive underlying malignancy.
Critical Care | 2013
Luciano C. P. Azevedo; Marcelo Park; Jorge I. F. Salluh; Álvaro Réa-Neto; Vicente Cés de Souza-Dantas; Pedro Varaschin; Mirella Cristine de Oliveira; Paulo Fernando Gmm Tierno; Felipe Dal-Pizzol; Ulysses V. A. Silva; Marcos Knibel; Antonio Paulo Nassar; Rossine A Alves; Juliana C Ferreira; Cassiano Teixeira; Valeria Rezende; Amadeu Martinez; Paula M Luciano; Guilherme Schettino; Márcio Soares
IntroductionContemporary information on mechanical ventilation (MV) use in emerging countries is limited. Moreover, most epidemiological studies on ventilatory support were carried out before significant developments, such as lung protective ventilation or broader application of non-invasive ventilation (NIV). We aimed to evaluate the clinical characteristics, outcomes and risk factors for hospital mortality and failure of NIV in patients requiring ventilatory support in Brazilian intensive care units (ICU).MethodsIn a multicenter, prospective, cohort study, a total of 773 adult patients admitted to 45 ICUs over a two-month period requiring invasive ventilation or NIV for more than 24 hours were evaluated. Causes of ventilatory support, prior chronic health status and physiological data were assessed. Multivariate analysis was used to identifiy variables associated with hospital mortality and NIV failure.ResultsInvasive MV and NIV were used as initial ventilatory support in 622 (80%) and 151 (20%) patients. Failure with subsequent intubation occurred in 54% of NIV patients. The main reasons for ventilatory support were pneumonia (27%), neurologic disorders (19%) and non-pulmonary sepsis (12%). ICU and hospital mortality rates were 34% and 42%. Using the Berlin definition, acute respiratory distress syndrome (ARDS) was diagnosed in 31% of the patients with a hospital mortality of 52%. In the multivariate analysis, age (odds ratio (OR), 1.03; 95% confidence interval (CI), 1.01 to 1.03), comorbidities (OR, 2.30; 95% CI, 1.28 to 3.17), associated organ failures (OR, 1.12; 95% CI, 1.05 to 1.20), moderate (OR, 1.92; 95% CI, 1.10 to 3.35) to severe ARDS (OR, 2.12; 95% CI, 1.01 to 4.41), cumulative fluid balance over the first 72 h of ICU (OR, 2.44; 95% CI, 1.39 to 4.28), higher lactate (OR, 1.78; 95% CI, 1.27 to 2.50), invasive MV (OR, 2.67; 95% CI, 1.32 to 5.39) and NIV failure (OR, 3.95; 95% CI, 1.74 to 8.99) were independently associated with hospital mortality. The predictors of NIV failure were the severity of associated organ dysfunctions (OR, 1.20; 95% CI, 1.05 to 1.34), ARDS (OR, 2.31; 95% CI, 1.10 to 4.82) and positive fluid balance (OR, 2.09; 95% CI, 1.02 to 4.30).ConclusionsCurrent mortality of ventilated patients in Brazil is elevated. Implementation of judicious fluid therapy and a watchful use and monitoring of NIV patients are potential targets to improve outcomes in this setting.Trial registrationClinicalTrials.gov NCT01268410.
Annals of the American Thoracic Society | 2015
Viviane Bogado Leite Torres; Luciano C. P. Azevedo; Ulysses V. A. Silva; Pedro Caruso; André P. Torelly; Eliezer Silva; Frederico Bruzzi de Carvalho; Arthur Vianna; P Souza; José R. A. Azevedo; Nelson Spector; Fernando A. Bozza; Jorge I. F. Salluh; Márcio Soares
RATIONALE Sepsis is a major cause of mortality among critically ill patients with cancer. Information about clinical outcomes and factors associated with increased risk of death in these patients is necessary to help physicians recognize those patients who are most likely to benefit from ICU therapy and identify possible targets for intervention. OBJECTIVES In this study, we evaluated cancer patients with sepsis chosen from a multicenter prospective study to characterize their clinical characteristics and to identify independent risk factors associated with hospital mortality. METHODS Subgroup analysis of a multicenter prospective cohort study conducted in 28 Brazilian intensive care units (ICUs) to evaluate adult cancer patients with severe sepsis and septic shock. We used logistic regression to identify variables associated with hospital mortality. MEASUREMENTS AND MAIN RESULTS Of the 717 patients admitted to the participating ICUs, 268 (37%) had severe sepsis (n = 142, 53%) or septic shock (n = 126, 47%). These patients comprised the population of the present study. The mean score on the third version of the Simplified Acute Physiology Score was 62.9 ± 17.7 points, and the median Sequential Organ Failure Assessment score was 9 (7-12) points. The most frequent sites of infection were the lungs (48%), intraabdominal region (25%), bloodstream as primary infection (19%), and urinary tract (17%). Half of the patients had microbiologically proven infections, and Gram-negative bacteria were the most common pathogens causing sepsis (31%). ICU and hospital mortality rates were 42% and 56%, respectively. In multivariable analysis, the number of acute organ dysfunctions (odds ratio [OR], 1.48; 95% confidence interval [CI], 1.16-1.87), hematological malignancies (OR, 2.57; 95% CI, 1.05-6.27), performance status 2-4 (OR, 2.53; 95% CI, 1.44-4.43), and polymicrobial infections (OR, 3.74; 95% CI, 1.52-9.21) were associated with hospital mortality. CONCLUSIONS Sepsis is a common cause of critical illness in patients with cancer and remains associated with high mortality. Variables related to underlying malignancy, sepsis severity, and characteristics of infection are associated with a grim prognosis.
Intensive Care Medicine | 2017
Márcio Soares; Ulysses V. A. Silva; S Walter HomenaJr.; Guilherme Côrtes Fernandes; Ana Paula Pierre de Moraes; L Brauer; Mariza da Fonte Andrade Lima; Fernando Vinicius Cesar De Marco; Fernando A. Bozza; Jorge I. F. Salluh
Fernando A. Bozza. Fundacao Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Documento produzido em parceria ou por autor vinculado a Fiocruz, mas nao consta a informacao no documento.
Annals of Intensive Care | 2018
C. Barth; Márcio Soares; A. C. Toffart; Jean-François Timsit; G Burghi; C. Irrazabal; Natalie Pattison; E. Tobar; B. F. Almeida; Ulysses V. A. Silva; L. C. Azevedo; Antoine Rabbat; C. Lamer; A. Parrot; V. C. Souza-Dantas; F. Wallet; François Blot; G. Bourdin; C. Piras; J. Delemazure; M. Durand; Jorge I. F. Salluh; Elie Azoulay; Virginie Lemiale
BackgroundAlthough patients with advanced or metastatic lung cancer have poor prognosis, admission to the ICU for management of life-threatening complications has increased over the years. Patients with newly diagnosed lung cancer appear as good candidates for ICU admission, but more robust information to assist decisions is lacking. The aim of our study was to evaluate the prognosis of newly diagnosed unresectable lung cancer patients.MethodsA retrospective multicentric study analyzed the outcome of patients admitted to the ICU with a newly diagnosed lung cancer (diagnosis within the month) between 2010 and 2013.ResultsOut of the 100 patients, 30 had small cell lung cancer (SCLC) and 70 had non-small cell lung cancer. (Thirty patients had already been treated with oncologic treatments.) Mechanical ventilation (MV) was performed for 81 patients. Seventeen patients received emergency chemotherapy during their ICU stay. ICU, hospital, 3- and 6-month mortality were, respectively, 47, 60, 67 and 71%. Hospital mortality was 60% when invasive MV was used alone, 71% when MV and vasopressors were needed and 83% when MV, vasopressors and hemodialysis were required. In multivariate analysis, hospital mortality was associated with metastatic disease (OR 4.22 [1.4–12.4]; p = 0.008), need for invasive MV (OR 4.20 [1.11–16.2]; p = 0.030), while chemotherapy in ICU was associated with survival (OR 0.23, [0.07–0.81]; p = 0.020).ConclusionThis study shows that ICU management can be appropriate for selected newly diagnosed patients with advanced lung cancer, and chemotherapy might improve outcome for patients with SCLC admitted for cancer-related complications. Nevertheless, tumors’ characteristics, numbers and types of organ dysfunction should be taken into account in the decisional process before admitting these patients in ICU.
Critical Care Medicine | 2015
Luciano C. P. Azevedo; Fernando Ignacio; Ulysses V. A. Silva; Vicente Cés de Souza-Dantas; Leandro U Taniguchi; Jorge I. F. Salluh; Álvaro Réa-Neto; Márcio Soares
Copyright
Critical Care | 2010
Suzana M. Lobo; Márcio Soares; André P. Torelly; P Mello; Ulysses V. A. Silva; José Mario Meira Teles; Eliezer Silva; Pedro Caruso; Gilberto Friedman; P Souza; Álvaro Réa-Neto; A Vianna; Marcelo de Oliveira Maia; Jorge Ibrain Figueira Salluh
Critically ill cancer patients are at increased risk for acute kidney injury (AKI), but studies on these patients are scarce and were all single centered, conducted in specialized ICUs. The aim of this study was to evaluate the characteristics and outcomes in a prospective cohort of ICU cancer patients with AKI.
Intensive Care Medicine | 2017
Elie Azoulay; Peter Pickkers; Márcio Soares; Anders Perner; Jordi Rello; Philippe R. Bauer; Andry Van de Louw; Pleun Hemelaar; Virginie Lemiale; Fabio Silvio Taccone; Ignacio Martin Loeches; Tine Sylvest Meyhoff; Jorge I. F. Salluh; Peter Schellongowski; Katerina Rusinova; Nicolas Terzi; Sangeeta Mehta; Massimo Antonelli; Achille Kouatchet; Andreas Barratt-Due; Miia Valkonen; Precious P. Landburg; Fabrice Bruneel; Ramin Brandt Bukan; Frédéric Pène; Victoria Metaxa; Anne Sophie Moreau; Virginie Souppart; G Burghi; Christophe Girault
Journal of Clinical Oncology | 2016
Márcio Soares; Fernando A. Bozza; Luciano C. P. Azevedo; Ulysses V. A. Silva; Thiago Domingos Corrêa; Fernando Colombari; André P. Torelly; Pedro Varaschin; William N. Viana; Marcos Freitas Knibel; Moyzés Damasceno; Rodolfo Andrade Espinoza; Marcus Ferez; Juliana G. Silveira; Suzana A. Lobo; Ana Paula Pierre de Moraes; Ricardo. A. Lima; Alexandre Guilherme Ribeiro de Carvalho; Pedro Emmanuel Alvarenga Americano do Brasil; Jeremy M. Kahn; Derek C. Angus; Jorge I. F. Salluh